{
    "clinical_study": {
        "@rank": "50380", 
        "arm_group": {
            "arm_group_label": "teriflunomide dose 1", 
            "arm_group_type": "Experimental", 
            "description": "Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To assess the pharmacokinetic (PK) parameters of teriflunomide after a single oral dose of\n      14 mg administration in Chinese healthy subjects\n\n      Secondary Objective:\n\n      To assess the safety and tolerability after a single oral dose of 14 mg teriflunomide in\n      Chinese healthy subjects"
        }, 
        "brief_title": "A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Screening: 2 to 21 days before inclusion (Day -21 to Day -2)\n\n        -  Institutionalization period: 6 days including 1 treatment day  (Day -1 to Day 6,\n           treatment on Day 1)\n\n        -  Follow-up: 7-10 days (may be extended)\n\n        -  End of study: Day 38 to Day 41  (may be extended)\n\n        -  Total study duration: maximum 9 weeks"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n        Male or female subjects, between 18 and 45 years of age, inclusive. Body weight between\n        50.0 and 95.0 kg, inclusive, if male, and between 45.0 and 85.0 kg, inclusive, if female,\n        body mass index between 19.0 and 24.0 kg/m2, inclusive.\n\n        Certified as healthy by a comprehensive clinical assessment and lab test. Subject must use\n        an appropriate contraception method. Having given written informed consent prior to any\n        procedure related to the study.\n\n        Exclusion criteria:\n\n        Blood donation, any volume, within 3 months before inclusion. Symptomatic postural\n        hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension\n        defined by a decrease in systolic blood pressure \u226520 mmHg within 3 minutes when changing\n        from the supine to the standing position.\n\n        Excessive consumption of beverages with xanthine bases (>4 cups or glasses per day).\n\n        If female, pregnancy (defined as positive \u03b2-hCG blood test), breast-feeding. Any\n        medication (including St John's Wort and traditional Chinese herb medicine) within 14 days\n        before the inclusion or within 5 times the elimination half-life or pharmacodynamic\n        half-life of that drug, with the exception of hormonal contraception or menopausal hormone\n        replacement therapy; any vaccination within the last 28 days.\n\n        Any consumption of citrus (grapefruit, orange, etc) or their juices within 5 days before\n        inclusion.\n\n        Subject (both male and female)  who disagrees to use an appropriate contraception method .\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046629", 
            "org_study_id": "PKM12788", 
            "secondary_id": "U1111-1152-4217"
        }, 
        "intervention": [
            {
                "arm_group_label": "teriflunomide dose 1", 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "Teriflunomide HMR1726", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "teriflunomide dose 1", 
                "description": "Pharmaceutical form:power Route of administration: oral", 
                "intervention_name": "cholestyramine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cholestyramine Resin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200025"
                }, 
                "name": "Investigational Site Number 156001"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetic parameters for teriflunomide determined from plasma concentration", 
            "safety_issue": "No", 
            "time_frame": "5 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046629"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "safety assessments (adverse events, laboratory data, vital sign, and ECG parameters)", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}